You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-L1 gastric cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification Trial in New York (Nivolumab, Capecitabine,

Recruiting
  • Metastatic Gastric Cancer
  • +2 more
  • New York, New York
    Bureau for Cancer Research
May 10, 2023

Serplulimab,Gastric Cancer, Adjuvant Therapy Trial in Shanghai (Serplulimab, Docetaxel, S1)

Recruiting
  • Serplulimab,Gastric Cancer, Adjuvant Therapy
  • Shanghai, China
    Zhang Zizhen
Mar 3, 2023

Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC Trial run by the NCI (N-803, Pembrolizumab, PD-L1 t-haNK)

Recruiting
  • Gastroesophageal Junction (GEJ) Cancers
  • Advanced HNSCC
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2023

PD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer Trial in Changchun (Drug: Toripalimab,

Recruiting
  • PD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer
  • Drug: Toripalimab, FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU)
  • Changchun, Ji Lin, China
    First Hospital of Jilin University
Jul 18, 2022

Recurrent/Metastatic Gastric Cancer Trial in Seoul (Nivolumab, Paclitaxel)

Completed
  • Recurrent/Metastatic Gastric Cancer
  • Nivolumab, Paclitaxel
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Sep 9, 2022

Skin Health and Quality of Life in Patients Receiving

Not yet recruiting
  • Lung Cancer
  • +7 more
  • EQ-5D-5L questionnaire
  • +2 more
  • Roma, Italy
    Roberto Iacovelli
May 17, 2023

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in Gyeonggi-do, Seoul (GEN-001, Avelumab)

Recruiting
  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • Gyeonggi-do, Korea, Republic of
  • +4 more
Jun 14, 2022

Solid Tumor, NSCLC, Cervical Cancer Trial in China (Afuresertib, Nab paclitaxel, Docetaxel)

Recruiting
  • Solid Tumor
  • +5 more
  • Beijing, Beijing, China
  • +4 more
Jul 15, 2022

Gastric Cancer Trial in Beijing (neoantigen tumor vaccine with or without PD-1/L1)

Not yet recruiting
  • Gastric Cancer
  • neoantigen tumor vaccine with or without PD-1/L1
  • Beijing, China
    Department of GI Oncology, Peking University Cancer Hospital,
Jan 26, 2022

Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma, Esophagus Adenocarcinoma Trial in Fuzhou (XBI-302 + Nivolumab)

Withdrawn
  • Gastric Adenocarcinoma
  • +2 more
  • XBI-302 + Nivolumab
  • Fuzhou, Fujian, China
    Fujian Cancer Hospital
Oct 19, 2021

Gastric Cancer, Peritoneal Carcinomatosis Trial in Chicago (Cisplatin, Mitomycin)

Recruiting
  • Gastric Cancer
  • Peritoneal Carcinomatosis
  • Chicago, Illinois
    University of Chicago
Jan 19, 2022

Gastric Cancer, Esophageal Cancer, Liver Cancer Trial in Beijing (neoantigen tumor vaccine with or without PD-1/L1)

Recruiting
  • Gastric Cancer
  • +2 more
  • neoantigen tumor vaccine with or without PD-1/L1
  • Beijing, Beijing, China
    PLA General Hospital
Jan 27, 2022

Nivolumab Plus Chemotherapy in First Line Treatment of Adult

Recruiting
  • Gastric Cancer
    • Hamburg, Germany
      Local Institution
    Feb 24, 2022

    NSCLC, Small Cell Lung Cancer, Urothelial Carcinoma Trial in United States (N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 +

    Active, not recruiting
    • Non-Small Cell Lung Cancer
    • +12 more
    • N-803 + Pembrolizumab
    • +9 more
    • Anchorage, Alaska
    • +34 more
    Apr 4, 2022

    Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)

    Recruiting
    • Digestive System Cancers
    • Beijing, China
      Peking University Cancer Hospital
    Oct 25, 2023

    Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin

    Recruiting
    • Gastric Cancer
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Institute and Hospital
    Oct 22, 2023

    Squamous Cell Carcinoma of Head and Neck, NSCLC, Hepatocellular Carcinoma Trial in Worldwide (KY1044, KY1044 and atezolizumab)

    Recruiting
    • Squamous Cell Carcinoma of Head and Neck
    • +11 more
    • New Haven, Connecticut
    • +12 more
    Nov 3, 2022

    Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (Atezolizumab, Trastuzumab, Capecitabine)

    Recruiting
    • Gastric Cancer
    • Gastroesophageal Junction Adenocarcinoma
    • Beijing, China
    • +9 more
    Mar 11, 2022

    Gastric Adenocarcinoma Trial (cadonilimab combined +paclitaxel (albumin-bound))

    Not yet recruiting
    • Gastric Adenocarcinoma
    • cadonilimab combined +paclitaxel (albumin-bound)
    • (no location specified)
    Nov 1, 2023

    Lung Cancer Trial (Centipeda minima+PD-1/PD-L1 inhibitor, PD-1/PD-L1 inhibitor)

    Not yet recruiting
    • Lung Cancer
    • Centipeda minima+PD-1/PD-L1 inhibitor
    • PD-1/PD-L1 inhibitor
    • (no location specified)
    Feb 17, 2023

    Solid Tumor, Breast Cancer, Small Cell and NSCLC Trial in Hackensack (RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior

    Recruiting
    • Solid Tumor
    • +15 more
    • RAPA-201 Rapamycin Resistant T Cells
    • Chemotherapy Prior to RAPA-201 Therapy
    • Hackensack, New Jersey
      Hackensack University Medical Center
    Dec 23, 2021

    Advanced Solid Tumor Trial in Chengdu (Dual-targeting CLDN18.2 and PD-L1 CAR-T cells)

    Not yet recruiting
    • Advanced Solid Tumor
    • Dual-targeting CLDN18.2 and PD-L1 CAR-T cells
    • Chengdu, Sichuan, China
      West China Hospital, Sichuan University
    Oct 9, 2023

    Biliary Tract Cancer, Candonilimab, Claudin 18.2 Trial in Shanghai (cardonilizumab, LM-302)

    Recruiting
    • Biliary Tract Cancer
    • +2 more
    • Shanghai, China
      Zhongshan hospital, Fudan University
    Aug 12, 2023

    Gastric Cancer, HER2-low-expressing Gastric Cancer Trial in Shanghai (Disitamab Vedotin, Toripalimab)

    Recruiting
    • Gastric Cancer
    • HER2-low-expressing Gastric Cancer
    • Shanghai, China
      Shanghai East Hospital
    Oct 9, 2023

    Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Nanjing (neoadjuvant chemo-hypofractionated radiotherapy plus PD-1

    Active, not recruiting
    • Gastric or Gastroesophageal Junction Adenocarcinoma
    • neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)
    • Nanjing, Jiangsu, China
      Jiangsu Cancer Hospital
    Jul 4, 2023